Compare Ascendis Pharma A/S (ASND) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs FedEx Corporation — how do they compare? Ascendis Pharma A/S trades at $256.57 (market cap $16.67B), while FedEx Corporation trades at $325.74 (market cap $76.28B). The key difference: FedEx Corporation is far larger — about 4.6× Ascendis Pharma A/S's market cap, and FedEx Corporation pays a 1.51% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | FDX | |
|---|---|---|
Market Cap | $16.67B | $76.28B |
Sector | Health | Industrials |
52-Week High | $277.18 | $338.75 |
52-Week Low | $189.74 | $180.51 |
Enterprise Value | $17.04B | $105.91B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
FedEx (FDX) trades at $325.53, up 0.14% on the day, with a bullish technical signal and strong analyst backing. Recent earnings beats in Q4 2025 and Q1 2026, with EPS of $5.25 and $6.31 respectively against expectations, highlight operational strength. The company's Network 2.0 initiative aims for $2 billion in annual savings, supporting margin improvement. Valuation ratios like P/E of 17.38 and P/S of 0.81 appear reasonable relative to historical levels.
Outlook is positive with a consensus price target of $360.27, implying 11% upside, driven by cost-cutting and premium revenue shifts. Risks include softer freight demand and debt levels, but institutional buying and bullish sentiment suggest confidence in FedEx's execution amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
